Genome Editing for the β-Hemoglobinopathies

Adv Exp Med Biol. 2017:1013:203-217. doi: 10.1007/978-1-4939-7299-9_8.

Abstract

The β-hemoglobinopathies are diverse set of disorders caused by mutations in the β-globin (HBB) gene. Because HBB protein is a critical component (along with α-globin, heme, and iron) of hemoglobin, the molecule essential for oxygen delivery to tissues, mutations in HBB can result in lethal diseases or diseases with multi-organ dysfunction. HBB mutations can be roughly divided into two categories: those that cause a dysfunctional protein (such as sickle cell disease but also including varied diseases caused by high-affinity hemoglobins, low-affinity hemoglobins, and methemoglobinemia) and those that cause the insufficient production of HBB protein (β-thalassemia). Sickle cell disease and β-thalassemia are both the most prevalent and the most devastating of the β-hemoglobinopathies.

Keywords: Genome editing; HBB gene; Nucleases; Sickle cell disease; β-hemoglobinopathies; β-thalassemia.

MeSH terms

  • Anemia, Sickle Cell / genetics
  • Anemia, Sickle Cell / therapy*
  • Gene Editing / methods*
  • Gene Editing / trends
  • Hematopoietic Stem Cell Transplantation / methods*
  • Hematopoietic Stem Cells / metabolism*
  • Humans
  • Mutation
  • Transplantation, Homologous
  • beta-Globins / genetics
  • beta-Thalassemia / genetics
  • beta-Thalassemia / therapy*

Substances

  • beta-Globins